← board
FBIO
distress 2/10 · well-funded / low risk$3.53-1%today-19% from 52w high
Lead: AL amyloidosis
Revenue
$16M
Liquidity
$256M
Runway
—
Shares 1y
+1074%
Price & events
+1.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
+3.2%
1W
+11.7%
1M
+58.3%
3M
+3.8%
6M
+82.9%
1Y
+35.2%
2Y
-92.3%
5Y
-92.8%
All
Overview
- Market Cap
- $291.13M
- Enterprise Value
- $72.79M
- Volume
- 38.54K
- 52 Week Range
- $1.81 – $4.38
- Total Shares
- 82.47M
- Float Shares
- 23.09M
- Short %
- 20.69%
- % Held by Insiders
- 22.79%
- % Held by Institutions
- 24.76%
- RVOL
- 0.07x
- Beta
- 1.21
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- as early as 2025filing acceptanceFiled (NDA/BLA)CAEL-101 · Potential FDA acceptance of BLA submissionSEC 8-K
- as early as 2025regulatory submissionFiled (NDA/BLA)CAEL-101 · Potential BLA filingSEC 8-K
- 2024-07-05withdrawalPaused dividend payments on Series A Preferred StockSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 82,474,127 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-02-23HC Wainwright & Co.Buy
- 2025-08-21HC Wainwright & Co.Buy
- 2025-03-11Roth MKMBuy
- 2024-11-18HC Wainwright & Co.Buy
- 2024-07-19HC Wainwright & Co.Buy
Competitors — AL amyloidosis
Recent news
- 2026-07-22Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy - Seeking Alpha
- 2026-07-17Fortress Biotech Achieves 73.6% Return in the Stock Market Over Past Year - MarketsMojo
- 2026-07-10Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock Declines - Earnings Weakness Phase - dars.gov.et
- 2026-07-08Fortress Biotech (FBIO) Edges Lower Amid Quiet Trading, Holds Above Key Support - Bollinger Walk - dars.gov.et
- 2026-07-07Fortress Biotech Preferred Shares (FBIOP) Slide 1.98% as Support Test Approaches - Put Flow Alert - dars.gov.et
- 2026-07-03Fortress Biotech Inc highlights its specialty pharma model as investors assess long-term prospects - Ad-hoc-news.de
- 2026-06-25FBIO Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25Form 4 Fortress Biotech Inc For: 24 June By Investing.com - Investing.com Nigeria
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.